SDGR Share Price Performance
US$11.87
-10.88 (-47.82%)
49.5% undervalued intrinsic discount
US$23.50
Fair Value
Price US$11.87
AnalystConsensusTarget US$23.50
davidlsander US$43.20
AnalystLowTarget US$13.00
Fair ValueUS$23.50
Share Pricen/a
Schrödinger, Inc. Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 66 Fair Values set on narratives written by author
SDGR Community Narratives
AN
Fair Value US$23.5 49.5% undervalued intrinsic discount
Pipeline And Predictive Toxicology Will Unlock Future Success
0users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
DA
Fair Value US$43.2 72.5% undervalued intrinsic discount
Schrödinger will Transform Drug Discovery with 24% Growth
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$13 8.7% undervalued intrinsic discount
Margins And Revenue Challenges Will Slow Progress Yet Kindle Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Schrödinger will Transform Drug Discovery with 24% Growth
Schrödinger stands at the confluence of biotechnology, materials science, and enterprise software, pioneering a transformation in the field of molecular discovery. The company has moved beyond the traditional silos of either a software provider or a drug developer to create a hybrid enterprise.Read more
23
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DA
US$43.2
72.5% undervalued intrinsic discount
Fair Value
Profit Margin
13.42%
Future PE
39.4x
Price in 2030
US$63.56
Margins And Revenue Challenges Will Slow Progress Yet Kindle Potential
Key Takeaways Reliance on large pharma clients and high R&D outlays limit revenue growth and keep earnings negative despite new product initiatives and expanding collaborations. Intensifying competition, slow adoption by new customers, and regulatory uncertainties challenge sustained pricing power and margin improvement.Read more
45
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13
8.7% undervalued intrinsic discount
Fair Value
Profit Margin
6.37%
Future PE
60.65x
Price in 2029
US$16.62
Pipeline And Predictive Toxicology Will Unlock Future Success
Key Takeaways Advancements in clinical programs and strategic partnerships position the company for long-term revenue growth and improved earnings visibility. Increasing demand and improvements in AI-driven software drive higher market penetration, recurring SaaS revenues, and stronger operating margins.Read more
261
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
24users have followed this narrative
AN
US$23.5
49.5% undervalued intrinsic discount
Fair Value
Profit Margin
6.33%
Future PE
79.42x
Price in 2029
US$30.02
Accelerating AI Adoption And Precision Medicine Will Empower Computational Breakthroughs
Key Takeaways Accelerating adoption of AI-powered software, cloud solutions, and regulatory engagement could drive substantial growth in both revenue and market reach. Strategic positioning in precision medicine and expanding collaborations position the company for sustained earnings growth and outsized industry influence.Read more
34
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$33
64.0% undervalued intrinsic discount
Fair Value
Profit Margin
8.77%
Future PE
86.18x
Price in 2028
US$41.1
Trending Discussion
Recently Updated Narratives
DA
Schrödinger will Transform Drug Discovery with 24% Growth
Fair Value: US$43.2 72.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDGR: Sector Pressures And Hosted Software Shift Will Reset 2026 Expectations
Fair Value: US$13 8.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDGR: Hosted Software Shift Will Reshape Future Profitability Profile
Fair Value: US$23.5 49.5% undervalued intrinsic discount
24 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Schrödinger, Inc. Key Details
About SDGR
- Founded
- 1990
- Employees
- 850
- CEO
- WebsiteView website
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
